Organogenesis stock at USD 1.11, 0.90 percent above its low

Published on 10/15/2026 at 21:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are set for November 5, 2026. Organogenesis stock costs EUR 0.99 on October 15, 2026 at 9:05 p.m. CEST, down 2.54 percent on Nasdaq.

Price and reporting date

Organogenesis stock stood 0.90 percent above its 52-week low on October 15, 2026.
Organogenesis will report third-quarter fiscal 2026 results on November 5, 2026.
Organogenesis stock costs EUR 0.99 at Lang & Schwarz on October 15, 2026 at 9:05 p.m. CEST, down 2.54 percent on Nasdaq.
Organogenesis had a market capitalization of USD 143.0 million on October 15, 2026.

ORGO, US68621F1021, Illustration mit AI erstellt.

Organogenesis stock stood at USD 1.11 on Nasdaq on October 15, 2026, 0.90 percent above its 52-week low of USD 1.10. The company has set November 5, 2026, for its third-quarter fiscal 2026 results, giving investors a defined date for the next major operating update. Nasdaq trading was down 2.54 percent on the day.

Results date sets the next checkpoint

Organogenesis will report its third-quarter fiscal 2026 financial results after the market closes on November 5, 2026, and will hold its earnings call at 5:00 p.m. Eastern Time. The date was published by Organogenesis on October 12, 2026.

The reporting date matters because the company entered the second half of fiscal 2026 with a smaller operating base than its prior-year profile. Organogenesis operates in advanced wound care, surgical products and sports medicine, with products sold to hospitals, wound care centers, ambulatory surgical centers and physician offices.

Stock remains near its yearly low

The Nasdaq price of USD 1.11 sits only 0.90 percent above the 52-week low of USD 1.10 and 84.32 percent below the 52-week high of USD 7.08. The stock therefore remains positioned at the lower end of its annual range, while the October 15 move provides the immediate trading signal.

The current market capitalization was USD 143.0 million on October 15, 2026. Organogenesis had a trailing price-to-earnings ratio of minus 1.34 and no trailing dividend yield. Its regenerative medicine portfolio includes advanced wound care products such as Apligraf, Dermagraft and PuraPly AM.

Comparison with peers

Organogenesis (Nasdaq, USD): minus 2.54 percent, P/E minus 1.34, market capitalization USD 143.0 million

Integra LifeSciences (Nasdaq, USD): plus 3.23 percent, P/E minus 147.08, market capitalization USD 1.1 billion

MiMedx Group (Nasdaq, USD): minus 0.53 percent, P/E 116.88, market capitalization USD 681.4 million

Price in euros after hours

At Lang & Schwarz, Organogenesis stock was trading at EUR 0.99 on October 15, 2026 at 9:05 p.m. CEST. The quote reflects the after-hours phase in Berlin, while Nasdaq trading remained the relevant home-market reference for the day's move.